BioSpace News Archive

Business

OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights

OmniAb, Inc. (NASDAQ: OABI) reported financial results for the three and nine months ended September 30, 2022 and provided operating and program updates.

November 15, 2022
·
10 min read
Business

Antibe Reports Q2 2023 Interim Financial and Operating Results

Antibe Therapeutics Inc. has filed its financial and operating results for the fiscal quarter ended September 30, 2022.

November 15, 2022
·
5 min read
Rally Foundation Benefit Bash Raises US $3.36M for Childhood Cancer Research

On Friday, November 11, Rally Foundation for Childhood Cancer Research hosted its 15th Annual Benefit Bash, sponsored by Delta Air Lines, raising more than $3.36 million in critical funding for advances in the fight against childhood cancer.

November 15, 2022
·
3 min read
Pharm Country

Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in 22q11.2 Deletion Syndrome

Zynerba Pharmaceuticals, Inc. today announced that the European Commission (EC) has granted orphan drug designation to cannabidiol, the active ingredient in its transdermal gel, Zygel™, for the treatment of 22q11.2 deletion syndrome (22q).

November 15, 2022
·
7 min read
Business

Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Qualigen Therapeutics, Inc. today announces its financial results for the third quarter ended September 30, 2022, and provides an update on its therapeutic pipeline and other corporate developments.

November 15, 2022
·
12 min read
Business

Acerus Reports Third Quarter 2022 Financial Results

Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three and nine-month period ended September 30, 2022.

November 15, 2022
·
13 min read
Drug Development

Alphyn Biologics Completes First Cohort of Phase2a Clinical Trial of Topical Therapeutic for Mild-to-Moderate Atopic Dermatitis

Alphyn Biologics announced today that it has completed the first cohort of its Phase2a clinical trial of AB-101a, a topical therapeutic candidate for mild-to-moderate atopic dermatitis (AD) in adults and children as young as 2 years old.

November 15, 2022
·
2 min read
Pharm Country

Soligenix to Receive $1.2 M in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

Soligenix, Inc. announced today that it has received preliminary approval for a tax credit from the New Jersey Economic Development Authority’s (NJEDA) New Jersey Technology Business Tax Certificate Transfer program.

November 15, 2022
·
7 min read
Pharm Country

Organon To Present at the Piper Sandler 34th Annual Healthcare Conference

Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 34 th Annual Healthcare Conference on Tuesday, November 29th, 2022 at 9:00 a.m. EST.

November 15, 2022
·
1 min read
Business

ElevateBio and Affini-T Therapeutics Announce Partnership to Advance Affini-T’s T Cell Therapy Programs Targeting Core Oncogenic Drivers

ElevateBio, LLC and Affini-T Therapeutics, today announced a partnership to advance Affini-T’s engineered TCR-T therapies focused on KRAS (Kirsten rat sarcoma viral oncogene homolog), one of the most prevalent oncogenic driver mutations in solid tumor cancers.

November 15, 2022
·
5 min read